Alexion buys Taligen for $111 million, complementing focus on complement system
This article was originally published in Scrip
Executive Summary
Alexion Pharmaceuticals has acquired private owned Taligen Therapeutics for $111 million cash up front and future potential milestone payments in a deal that many analysts say is a good strategic fit, since Taligen has several preclinical candidates targetting the complement pathway, including one for age-related macular degeneration (AMD), while the research fully aligns with Alexion's focus.